GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. 1,2 Both SWIFT-1 and SWIFT-2 …
Depemokimab accepted for review by the European Medicines Agency ... - GSK
Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions. 1 Depemokimab's extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results ...
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized,...
Phase III Trials Show Depemokimab Reduces Severe Asthma …
Jun 12, 2024 · In addition to SWIFT-1 and SWIFT-2, GSK is conducting the NIMBLE study, which evaluates the efficacy and safety of depemokimab in patients transitioning from other IL-5-targeting therapies, such as mepolizumab or benralizumab. An open-label extension study, AGILE, is also underway to further assess long-term outcomes.
GSK to Approach FDA With Positive Phase III Data For Long
Sep 9, 2024 · GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it for an estimated $4 billion in peak sales if approved.
GSK’s twice-yearly asthma drug clears two phase 3 trials
5 days ago · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
Depemokimab applications accepted for review in China and …
2 days ago · Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions. 1 Depemokimab's extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results ...
GSK's depemokimab shows promise in Phase III CRSwNP trials
Oct 15, 2024 · UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces …
Oct 14, 2024 · On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with...
GSK announces positive phase III results from ANCHOR trials for ...
Oct 14, 2024 · Depemokimab’s extended half-life, high potency and high binding affinity for IL-5 means it has the potential to provide sustained inhibition of broad inflammatory functions with dosing once every six-months. The phase III programme includes evaluation of depemokimab in other IL-5 mediated diseases.